ATE439854T1 - Proteinhydrolysat mit antidiabetischer wirkung - Google Patents

Proteinhydrolysat mit antidiabetischer wirkung

Info

Publication number
ATE439854T1
ATE439854T1 AT05804084T AT05804084T ATE439854T1 AT E439854 T1 ATE439854 T1 AT E439854T1 AT 05804084 T AT05804084 T AT 05804084T AT 05804084 T AT05804084 T AT 05804084T AT E439854 T1 ATE439854 T1 AT E439854T1
Authority
AT
Austria
Prior art keywords
blood sugar
protein hydrolyzate
antidiabetic effect
hyperglycemia
lowering
Prior art date
Application number
AT05804084T
Other languages
English (en)
Inventor
Kyoichi Kagawa
Toshihiko Naruse
Chizuko Fukuhama
Original Assignee
Mg Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mg Pharma Inc filed Critical Mg Pharma Inc
Application granted granted Critical
Publication of ATE439854T1 publication Critical patent/ATE439854T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
AT05804084T 2004-11-15 2005-11-15 Proteinhydrolysat mit antidiabetischer wirkung ATE439854T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62784304P 2004-11-15 2004-11-15
PCT/JP2005/021318 WO2006052031A1 (en) 2004-11-15 2005-11-15 Protein hydrolysate with antidiabetic effect

Publications (1)

Publication Number Publication Date
ATE439854T1 true ATE439854T1 (de) 2009-09-15

Family

ID=36336683

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05804084T ATE439854T1 (de) 2004-11-15 2005-11-15 Proteinhydrolysat mit antidiabetischer wirkung

Country Status (12)

Country Link
US (1) US20090155376A1 (de)
EP (1) EP1824501B1 (de)
JP (1) JP4808218B2 (de)
KR (1) KR101219146B1 (de)
CN (1) CN101060854B (de)
AT (1) ATE439854T1 (de)
AU (1) AU2005302921B2 (de)
CA (1) CA2585442A1 (de)
DE (1) DE602005016144D1 (de)
DK (1) DK1824501T3 (de)
ES (1) ES2328835T3 (de)
WO (1) WO2006052031A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5041780B2 (ja) * 2006-10-23 2012-10-03 エムジーファーマ株式会社 肝障害改善組成物
KR101244331B1 (ko) * 2007-08-07 2013-03-18 엠지 팜마 아이엔씨. 혈압강하제
JP4864064B2 (ja) * 2008-10-30 2012-01-25 エムジーファーマ株式会社 抗糖尿病作用を有するペプチドおよびその用途
CN107551258B (zh) * 2016-06-30 2021-01-05 江西本草天工科技有限责任公司 用于预防和/或治疗肝损伤的vvyp
WO2018001273A1 (zh) * 2016-06-30 2018-01-04 江西本草天工科技有限责任公司 肽或其盐、其制备方法、及其制备预防和/或治疗肝损伤药物的用途
CN111937811A (zh) * 2020-08-19 2020-11-17 河源兴泰农牧股份有限公司 一种猪的生态健康养殖方法
JP2024102740A (ja) * 2023-01-19 2024-07-31 ロート製薬株式会社 疲労軽減又は疲労回復促進用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452888A (en) * 1980-07-10 1984-06-05 Terumo Corporation Process for producing a low-molecular weight peptide composition and nutrient agent containing the same
US4885486A (en) * 1987-12-21 1989-12-05 Sundstrand Corp. Darlington amplifier with high speed turnoff
CA1335567C (en) * 1988-02-02 1995-05-16 Kyoichi Kagawa Lipid metabolism promoting agent
US5723443A (en) * 1988-02-02 1998-03-03 Hankyu-Kyoei Bussan Co. Ltd. Lipid metabolism promoting agent and its use
JP2764276B2 (ja) * 1988-09-06 1998-06-11 仙味エキス株式会社 機能性新規ペプチド及びその利用
JP3137273B2 (ja) * 1992-06-16 2001-02-19 明治乳業株式会社 糖尿病に有効な組成物
JP3312944B2 (ja) * 1993-03-24 2002-08-12 伊藤ハム株式会社 脂肪細胞分化抑制ペプチド及び当該ペプチドを有効成分とする脂肪細胞分化抑制剤
JP2805194B2 (ja) * 1996-03-22 1998-09-30 阪急共栄物産株式会社 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤

Also Published As

Publication number Publication date
CN101060854A (zh) 2007-10-24
EP1824501A1 (de) 2007-08-29
DE602005016144D1 (de) 2009-10-01
KR20070086160A (ko) 2007-08-27
DK1824501T3 (da) 2009-12-21
HK1109563A1 (en) 2008-06-13
KR101219146B1 (ko) 2013-01-07
WO2006052031A1 (en) 2006-05-18
EP1824501B1 (de) 2009-08-19
AU2005302921A1 (en) 2006-05-18
JP4808218B2 (ja) 2011-11-02
US20090155376A1 (en) 2009-06-18
JP2008519758A (ja) 2008-06-12
ES2328835T3 (es) 2009-11-18
EP1824501A4 (de) 2008-04-09
CA2585442A1 (en) 2006-05-18
CN101060854B (zh) 2012-02-08
AU2005302921B2 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
WO2006044531A3 (en) Antisense modulation of ptp1b expression
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
BRPI0511703B8 (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
DK1181043T3 (da) Anvendelse af exendiner og agonister dertil til behandling af svangerskabsdiabetes mellitus
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
ECSP088506A (es) Derivados de tiadiazol como agentes antidiabeticos
ATE539748T1 (de) Glucokinaseaktivatoren
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
ECSP088509A (es) Derivados de 1,2,5-tiazolidinadiona sustituidos por 1-orto-fluoro-fenilo como inhibidores de ptp-asa
EA200870575A1 (ru) Композиции и способы лечения застойной сердечной недостаточности
WO2006097793A3 (en) Compositions capable of facilitating penetration across a biological barrier
BRPI0606727A (pt) terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
WO2008117125A3 (en) Compositions capable of facilitating penetration across a biological barrier
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
BRPI0407757A (pt) derivados de benzamida tetracìclica e métodos de uso dos mesmos
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20054769L (no) Substituerte fenylalkansyrer
WO2007067341A3 (en) Compositions and methods for increasing insulin sensitivity
WO2008043087A3 (en) Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
NO20054958L (no) Substitulerte aminokarboksylsyrer
Lee et al. Insulin secretory defect plays a major role in the development of diabetes in patients with distal pancreatectomy
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1824501

Country of ref document: EP